TMJ Dysfunction: Effects on Proprioception, Pain, and Body Awareness
Launched by NAGIHAN ACET · Aug 14, 2024
Trial Information
Current as of May 29, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called temporomandibular joint dysfunction (TMJ dysfunction), which affects the jaw joint and the muscles used for chewing. Many people, especially women and young adults aged 20 to 40, experience this issue, which can lead to problems like pain and difficulty with body awareness. The goal of the study is to understand how TMJ dysfunction impacts things like pain sensitivity and the ability to sense where your body is in space, which can be important for everyday activities.
To participate in this study, you need to be between 18 and 25 years old. However, if you have a history of neck injuries, certain chronic pain conditions, or are pregnant, you won't be eligible to join. If you qualify, you can expect to take part in assessments that measure how the TMJ dysfunction affects your pain levels and body awareness. This research is important because it aims to improve the understanding and diagnosis of TMJ dysfunction, which is often overlooked.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \*Being between 18-25 years old
- Exclusion Criteria:
- • History of cervical spine injuries or disorders
- • Chronic pain conditions or diagnosed musculoskeletal disorders
- • Previous neck or spine surgeries
- • Neurological or psychiatric conditions affecting proprioception or pain perception
- • Use of medications influencing pain sensitivity or proprioception
- • Pregnancy
About Nagihan Acet
Nagihan Acet is a pioneering clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies. With a robust portfolio of clinical trials spanning various therapeutic areas, Nagihan Acet emphasizes rigorous scientific methodology and patient-centric approaches. The organization is committed to fostering collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of safety, efficacy, and ethical conduct in all trial phases. By leveraging cutting-edge technologies and data analytics, Nagihan Acet aims to expedite the development of novel therapies and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
Nagihan Acet, Phd.
Study Director
Atılım University
Sena Nur Begen, MSc.
Principal Investigator
Atılım University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported